Physician profile
Malyssa Moore
NPI 1417690165
$3,880.12
in general payments reported to CMS, 2019-2025
27 companies · $1,654 in 2025
The $1,654 reported for 2025 was more than what 93% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $23.62 · 2022: $640 · 2023: $515 · 2024: $1,048 · 2025: $1,654.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,217.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,216.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $773.71 | 2023-2025 | Airsupra, Farxiga, Breztri |
| Abbvie INC. | $594.06 | 2022-2025 | |
| Novo Nordisk INC | $424.35 | 2022-2025 | Wegovy, Ozempic, Rybelsus |
| Lilly USA, LLC | $308.05 | 2023-2025 | Jardiance, Mounjaro, Zepbound |
| Amgen INC. | $248.48 | 2023-2025 | Repatha, Otezla, Otezla |
| Bayer Healthcare Pharmaceuticals INC. | $237.40 | 2025 | |
| Exact Sciences Corporation | $175.76 | 2025 | Cologuard Collection Kit |
| Phathom Pharmaceuticals, INC. | $165.28 | 2024-2025 | Voquezna |
| Pfizer INC. | $139.90 | 2022-2025 | |
| Hologic Sales and Service, LLC | $122.07 | 2023-2024 | Aptima, Thinprep 2000 Processor |
| Celgene Corporation | $116.45 | 2021-2024 | Zeposia |
| Sanofi-Aventis U.S. LLC | $92.74 | 2025 | |
| Idorsia Pharmaceuticals US INC | $89.81 | 2023-2024 | Quviviq |
| Almatica Pharma LLC | $63.64 | 2025 | Teriparatide, Loreev Xr |
| Lucid Diagnostics INC. | $50.38 | 2023 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $44.49 | 2024-2025 | Injectafer |
| E.R. Squibb & Sons, L.L.C. | $33.31 | 2023-2024 | Eliquis, Camzyos |
| Otsuka America Pharmaceutical, INC. | $28.42 | 2023 | Rexulti, Abilify Maintena |
| Astellas Pharma US INC | $25.56 | 2024 | Veozah |
| Boehringer Ingelheim Pharmaceuticals, INC. | $23.81 | 2025 | Jardiance |
| Protega Pharmaceutials INC | $21.47 | 2024 | Roxybond |
| Dexcom, INC. | $19.46 | 2024 | Dexcom G6 Transmitter |
| Intra-Sana Laboratories | $17.45 | 2025 | Reltone 200 Mg, Glycate, Reltone 400 Mg |
| Takeda Pharmaceuticals U.S.A., INC. | $17.16 | 2022 | |
| Glaxosmithkline, LLC. | $15.73 | 2024 | Shingrix |
| Biohaven Pharmaceutical Holding Company Ltd. | $15.61 | 2022 | |
| Scilex Pharmaceuticals INC. | $15.57 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Malyssa Moore listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.